Long-term trial supports CD19-targeted CAR T cells for relapsed/refractory CLL
2 Vues
• 07/14/23
0
0
Intégrer
administrator
Les abonnés
In this episode, Mark Geyer and colleagues demonstrate that second-generation CD19-targeted CAR T cell therapy following conditioning chemotherapy is tolerated in patients with relapsed/refractory CLL and can result in complete remission in a subset of patients…
Montre plus
Commentaires de Facebook
SORT BY-
Meilleures Commentaires
-
Derniers Commentaires